<DOC>
	<DOCNO>NCT00854139</DOCNO>
	<brief_summary>The primary objective cure multiple myeloma less toxic allogeneic bone marrow transplantation induce renal allograft tolerance mixed chimerism patient end stage renal failure multiple myeloma</brief_summary>
	<brief_title>Combined Bone Marrow Transplantation ( BMT ) Renal Transplant Multiple Myeloma ( MM ) With End Stage Renal Disease ( ESRD )</brief_title>
	<detailed_description>The induction transplantation tolerance involve specific elimination immune response transplant antigen . In realm kidney transplantation , tolerance mean recipient unable detect donor transplant kidney foreign , therefore recipient unable reject kidney . Donor bone marrow engraftment lead kidney graft tolerance animal model . Renal failure major complication multiple myeloma , plasma cell malignancy know cure allogeneic bone marrow transplantation . Standard bone marrow transplantation associate frequent toxicity patient multiple myeloma , generally consider option patient end stage renal disease . Myeloma patient exclude conventional renal transplantation protocol underlying malignancy . A less toxic bone marrow transplantation protocol , combine renal transplantation , could provide opportunity cure myeloma correction ESRD patient disease . In addition , successful marrow engraftment may expect lead state tolerance . Successful implementation tolerance would major benefit transplant recipient . The significance develop tolerance patient would spar disable complication indefinite immunosuppression , include infection , cataract , osteoporosis , diabetes , atherosclerosis , hypertension , malignancy</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Recipient Inclusion Criteria 1 . Participants endstage renal failure due association great equal stage II multiple myeloma 2 . Males females 18 65 year age . 3 . Participants must HLAmatched one six HLA A , B , DR antigenmismatched related donor , high resolution molecular DR allele determination . 4 . Men woman reproductive potential must agree use reliable method birth control treatment , woman period 2 year follow transplant . 5 . Participants dialysis CrCl &lt; 20 ml/min . 6 . Participants must receive medical clearance cardiologist prior condition transplant . 7 . Life expectancy great equal 6 month . 8 . Recipient ability understand provide inform consent . Recipient 1 . Evidence active infection define : ) clinical syndrome consistent viral bacterial infection ( e.g. , influenza , URI , UTI ) b ) fever clinical site infection identify , c ) microbiologically document infection , include , limited , bacteremia septicemia . 2 . Participation investigational drug use time enrollment . 3 . Contraindication therapy one propose agent ( e.g. , history allergy horse serum ATG ) . 4 . Serologic positivity HIV , HCV , HbsAg positivity . 5 . Women childbearing age adequate contraception maintain . 6 . Malignancy within past two year multiple myeloma , exclude basal cell carcinoma skin carcinoma situ cervix . 7 . AST/ALT &gt; 3 x normal bilirubin &gt; 1.5 x normal ( unless due Gilbert 's syndrome ) . 8 . Pregnancy uncontrolled serious medical illness relate underlying myeloma . 9 . Cardiac ejection fraction &lt; 40 % echocardiogram ; individual assessment ejection fraction 40 % 50 % . 10 . FEV1 &lt; 50 % predict correct DLCO &lt; 50 % predict . 11 . ABO blood group incompatibility hostvsgraft direction . Donor 1 . HLAmatched one six HLA A , B , DR antigenmismatched related male female donor 1865 year age . 2 . ECOG performance status 0 1 . 3 . Excellent health per conventional predonor history ( medical psychosocial evaluation ) . 4 . Acceptable laboratory parameter ( hematology normal nearnormal range ; liver function &lt; 2 time upper limit normal normal creatinine ) . 5 . Compatible ABO blood group . 6 . Negative donor lymphocyte crossmatch . 7 . No positive test viral infection ( HbsAg , HIV , HCV , HTLV1 ) . 8 . Cardiac/Pulmonary evaluation within normal limit ( CXR , EKG ) . 9 . Donor ability understand provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Renal failure</keyword>
	<keyword>Kidney transplant</keyword>
</DOC>